INTRODUCTION
Research groups with a gestalt similar to that of DuPont Phamaceuticals' Discovery Toxicology are arising within an increasing number of pharmaceutical and biotechnology companies and in the chemical industry. This commentary provides a historical perspective on this development and describes the diverse functions performed by 1 such group. The role of this group is illustrated by a series of investigations that affected the development of a novel class of anti-inflammatory drugs.
The traditional approach to drug development employed whole-animal pharmacology screens. The objective of such screens was to identify molecules with desired pharmacology, such as the abilities to reduce xenograft tumor growth, lower blood pressure, induce diuresis, etc. These approaches did not require a detailed understanding of biochemical mechanisms of action; this goal was pursued later in the development process. Although whole-animal screens did not afford the highthroughput screening currently employed, molecules identified by this approach necessarily had at least some of the desirable formulation characteristics, pharmacokinetics, pharmacodynamics, and toxicity information to facilitate drug candidate selection. The product of this process was a small number of lead molecules entering the safety evaluation process.
In recent years, the molecular definition of desirable therapeutic targets has displaced the whole-animal pharmacology screens with high-throughput, frequently noncell-based assays in New Leads Discovery groups. Large numbers of candidate pharmacophores can be selected and rapid progress made toward optimization of structure-activity relationships (SAR) before compounds are exposed either to cells or to whole animals. Proceeding into preclinical development following pharmacokinetic and pharmacodynamic optimization of such pharmacophores is often fraught with pitfalls related to unexpected manifestations of pharmacology and toxicity. By moving initial toxicology and pharmacology assessments earlier within the drug discovery process, potential drug liabilities may be identified prior to expenditure of considerable chemical and pharmacologic resources. The early identification of compound liabilities relating to pharmacology or toxicity is the essence of Discovery Toxicology.
IDENTIFICATION OF POTENTIAL LIABILITIES
The identification of potential liabilities begins with selection of a target protein, typically a receptor, enzyme, structural protein, or transcription factor. The desired therapeutic effect results from the agonism or antagonism of a function, activity, or signal transduced by such a target protein. Less frequently, a process or biochemical pathway is targeted for which the exact biochemical target is undefined. The precise description of a target, including the nucleotide sequence of its encoding open reading frame and regulatory elements, greatly facilitates the evaluation of potential liabilities. In situ hybridization and immunohistochemical or radioligandbinding approaches allow the definition of the tissue pattern of distribution of a target. The identification of target proteins and their level of expression in tissues (or cell lines) other than those of the therapeutically desired effect may provide clues as to sites of potential undesired pharmacologic effects. Transgenic and knockout mice may be used to define target protein functions and, potentially, to predict toxicities through detailed phenotypic analysis. Undesired pharmacologic interactions may or may not result in histologic alterations of tissues and are frequently detected in the broad receptor, enzyme, and functional screens offered by Nova, PanLabs, and Cerep, or in the battery of assays performed in Safety Pharmacology groups. The scientific literature should be scrutinized carefully for evidence that may reveal functions of target proteins located outside the desired site of action. In addition, homology searches for structurally related proteins or binding sites should be undertaken, and, where possible, the function, distribution, and effect of the xenobiotic on those closely related proteins should also be investigated. In many instances, this information may be present in the scientific literature.
The following example utilizes novel approaches to the early assessment of compound liabilities. Additional approaches are also discussed.
MAP KINASE INHIBITORS: POTENTIAL LIABILITIES AS ANTI-INFLAMMATORY AGENTS
Signal transduction pathways such as those of mitogen-activated protein (MAP) kinases are known to be activated in inflammatory diseases. To develop specific inhibitors of MAP kinases as anti-inflammatory agents, consideration must be given to circumstances in which MAP kinase activation is known to occur. A literature search revealed that p42/44 MAP (MEK) kinases are phosphorylated in activated neutrophils (5, 7) , in cytokine-stimulated hematopoietic cells (6, 11) , and in the hippocampus during events that evoke synaptic long-term potentiation, a paradigm strongly associated with shortterm memory acquisition (1, 4) . We conducted a series of studies with pharmacophores that inhibit the p42/44 MAP kinase pathway. The pharmacophores SJ327 and U0126 inhibit the target kinase with a Ki of 210 and 76 nM, respectively. These molecules do not have sufficient potency for consideration as drug development candidates but permit the study of pharmacology and toxicology in defined systems. A structurally dissimilar, less potent pharmacophore (PD98059) that also targets p42/44 MAP kinases and an inhibitor of the p38 MAP kinase pathway (SK&F 86002) were also employed. The p42/44 MAP kinase pathway was shown to be rapidly up-regulated in primary cultures of mouse bone marrow cells in the presence of a cocktail of hematopoietic cytokines. In the presence of completely inhibitory concentrations of SJ527 or U0126, the differentiation and numbers of erythroid and myeloid colonies were normal. Another inhibitor of cytokine-driven hematopoietic cell proliferation, rapamycin, was shown to markedly inhibit erythropoiesis and myelopoiesis in this system. The activation of the p42/44 MAP kinase pathway was thus identified as a potentially redundant cytokine-activated pathway in hematopoiesis, thus reducing concern that p42/44 MAP kinase pathway inhibitors could inhibit hematopoiesis in vitro.
In parallel studies, the p42/44 MAP kinase pathway was shown to be rapidly up-regulated during the leukotriene B4 and f-met,leu,phe-induced neutrophil respiratory burst (9) . In the presence of completely inhibitory I concentrations of SJ327 and U0126, a normal neutrophil respiratory burst was elicited. Moreover, these neutrophils killed Staphylococcus aureus to the same extent as control-activated neutrophils, suggesting that although it modulates neutrophil signal transduction, neutrophil bactericidal activity appeared to be unaltered by inhibition of MAP kinase. MAP kinase inhibitors are therefore unlikely to compromise host defense, at least with respect to neutrophilic clearance of pathogenic microorganisms.
The association of MAP kinase activation with longterm potentiation in the hippocampus has recently been recognized (1, 4) . Should the study of hippocampal explants demonstrate impaired synaptic long-term potentiation in response to initiating electrical stimuli, this novel class of anti-inflammatory drugs would potentially adversely affect the acquisition of memory. Preliminary data suggest that this is in fact the case. Such information could direct the design of drugs toward those that do not cross the blood-brain barrier.
NOVEL APPROACHES TO THE EARLY SAFETY EVALUATION OF THERAPEUTIC TARGETS
The number and diversity of approaches with which the potential toxic and pharmacologic liabilities of novel pharmacophores may be studied are as extensive as the areas from which they derive. Judicious evaluation of model systems may reveal approaches that can be implemented early in the drug development stage to identify and avoid potential liabilities. Transgenic mice are frequently touted as useful tools for evaluation of lia-bilities of pharmacologic targets. The advantages and limitations associated with the use of such mice are discussed below.
Unfortunately, the time required to create a knockout mouse is generally much longer than the typical times that elapse from selection of early chemistry leads to nomination of clinical candidates for preclinical toxicity study. In addition, compensatory alterations in knockout mice (redundancy) may lead to an underestimation of the potential liabilities of certain targets. The phenotypic development of conditioned knockout mice more closely recapitulates the pharmacologic inhibition of protein target molecules. In conditioned knockouts, genes flanked by lox-p sequences may be deleted in a potentially timeand tissue-specific manner by cre-recombinase. This technology, however, is not yet sufficiently advanced to reliably produce animals in an appropriate time frame for drug discovery. Knockout (8) for databases relevant to this field. In addition, the phenotypes of many human genetic disorders may provide valuable information regarding the potential liabilities or toxic mechanisms of action. Scriver's The Metabolic and Molecular Bases of Inherited Disease is a comprehensive collation of such material (10) .
New technologies, such as the microchip gene array (2), with its ability to monitor the regulation of thousands of genes simultaneously (genomics), and nuclear magnetic resonance (NMR) spectroscopic study of body fluids (metabonomics) (3), convey the promise of tests capable of rapidly detecting toxic and pharmacologic alterations in tissues. Consortia within the pharmaceutical and chemical industries are currently assessing the utility of these technologies.
Discovery toxicology is a nascent science in the chemical and pharmaceutical industries. The development of the exact genetic and biochemical definition of pharmacologic targets has permitted an equally precise assessment of compound liabilities early in drug discovery. Expertise in pathology, cell and molecular biology, biochemistry, and information technology is essential to a successful and flexible discovery toxicology team, as is the ability to fluidly interact across all potential therapeutic areas in drug discovery.
